Fate Therapeutics Announces That Data From Its Off-The-Shelf CAR T-Cell Programs FT819, FT839 And FT836 Will Be Featured At The American Society Of Gene And Cell Therapy Annual Meeting, May 11–15

Fate Therapeutics will present clinical and translational data from the systemic lupus erythematosus (SLE) arm of its ongoing Phase 1 trial evaluating FT819 in Regimen B, where FT819 is added to background maintenance therapy without the use of conditioning chemotherapy to drive B cell depletion and improve patient outcome.

The Company will also deliver an oral presentation on FT839, its next-generation, off-the-shelf dual-CAR T cell therapy designed to simultaneously target CD19 and CD38 to eliminate pathogenic B cells, plasma cells, and activated T and NK cells, while selectively sparing non-activated immune cells. This multi-antigen targeting approach is designed to offer a unique treatment option for patients with difficult-to-treat autoimmune diseases that are multicellular in pathology, including rheumatoid arthritis and type 1 diabetes.

Additionally, the Company will present preclinical data on FT836, its next-generation, off-the-shelf CAR T-cell therapy targeting the pan-tumor stress ligands MICA/B. FT836 is shown to demonstrate potent anti-tumor activity in preclinical studies across a broad range of liquid and solid tumors without the need for conditioning chemotherapy, and can be rationally combined with standard-of-care treatments, including monoclonal antibodies, immunomodulatory drugs, and chemotherapy for enhanced clinical efficacy.